Abstract 3535
Background
Prostate specific membrane antigen (PSMA) is a clinically validated target for the imaging of prostate cancer, and studies with therapeutic PSMA-targeted radionuclides are ongoing. A recent trial with pasotuxizumab (AMG 212), a canonical BiTE® molecule targeting PSMA, demonstrated preliminary antitumor activity in mCRPC. AMG 160 is a novel HLE BiTE® immuno-oncology therapy that directs T effector cells to tumor cells via dual binding to CD3 and PSMA.
Trial design
This open-label, ascending, multiple dose, phase 1 study (NCT03792841) will evaluate safety and tolerability, determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), characterize pharmacokinetics, and evaluate preliminary efficacy of AMG 160 in pts with mCRPC. The dose exploration will estimate the MTD or RP2D via Bayesian logistic regression modeling. The dose expansion will confirm the safety and tolerability of the selected dose and further evaluate pharmacodynamics and antitumor activity. AMG 160 will be given as a short-term IV infusion. In cycle 1, dexamethasone will be given within 1 hour prior to each dose of AMG 160; pts will be hospitalized for ≥72 hours after each AMG 160 infusion in cycle 1. Key inclusion criteria: age ≥18 years; histologically or cytologically confirmed mCRPC refractory to enzalutamide, abiraterone, and/or apalutamide; have failed 1–2 taxane-based regimens or are medically unsuitable for or refuse a taxane regimen; bilateral orchiectomy or on continuous androgen-deprivation therapy; evidence of progressive disease. Key exclusion criteria: active autoimmune disease or any other disease requiring immunosuppressive therapy (low dose prednisone permitted); central nervous system metastases or leptomeningeal disease; prior PSMA-targeted therapy. Preliminary antitumor activity will be assessed by RECIST 1.1 criteria with PCWG3 modifications, PSA response, duration of response, response as evaluated by 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT imaging, PFS/OS, and circulating tumor cell endpoints (CTC0 and CTC conversion). The study opened in January 2019; dose exploration is ongoing.
Clinical trial identification
NCT03792841.
Editorial acknowledgement
Dianne Tomita, MPH, a consultant to Amgen Inc.
Legal entity responsible for the study
Amgen Inc.
Funding
Amgen Inc.
Disclosure
B. Tran: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Astellas; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Research grant / Funding (institution), Non-remunerated activity/ies: Janssen-Cilag; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy: Tolmar; Advisory / Consultancy, Research grant / Funding (self): Ipsen; Research grant / Funding (self), Research grant / Funding (institution): AstraZeneca; Research grant / Funding (self): Pfizer; Research grant / Funding (self), Research grant / Funding (institution): Servier; Research grant / Funding (institution): Aslan; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Taiho; Research grant / Funding (institution): Akeso; Research grant / Funding (institution): Aptevo; Leadership role: ANZUP; Leadership role: GU Tumor Group - Cancer Trials Australia; Leadership role: Molecular Tumour Board - Victorian Comprehensive Cancer Centre. H. Kouros-Mehr: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen. A. Fermin: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen. L. Horvath: Research grant / Funding (self), Travel / Accommodation / Expenses: Astellas; Shareholder / Stockholder / Stock options, Spouse / Financial dependant, Spouse is an executive at this company: Connected Medical Solutions Pty Ltd. M. Rettig: Research grant / Funding (self): Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Johnson & Johnson. T. Dorff: Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Roche; Advisory / Consultancy: Seattle Genetics; Speaker Bureau / Expert testimony: Exelixis. S.T. Tagawa: Advisory / Consultancy, Research grant / Funding (institution): Medivation; Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma; Advisory / Consultancy, Research grant / Funding (institution): Dendreon; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Genentech; Advisory / Consultancy, Research grant / Funding (institution): Endocyte; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Immunomedics; Advisory / Consultancy, Research grant / Funding (institution): Karyopharm Therapeutics; Advisory / Consultancy, Research grant / Funding (institution): AbbVie; Advisory / Consultancy: Tolmar; Advisory / Consultancy: QED; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Progenics; Research grant / Funding (institution): Millenium; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Rexahn Pharmaceuticals; Research grant / Funding (institution): Newlink Genetics; Research grant / Funding (institution): Inovio Pharmaceuticals; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): AVEO; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Stem CentRx; Research grant / Funding (institution): Exelixis; Research grant / Funding (institution): Clovis. S.K. Subudhi: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Janssen; Research grant / Funding (self): Bristol-Myers Squibb; Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: Valeant; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Dendreon; Honoraria (self), Advisory / Consultancy, Shareholder / Stockholder / Stock options: Apricity Health; Honoraria (self), Advisory / Consultancy: Polaris; Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Speaker Bureau / Expert testimony: Bayer Healthcare Pharmaceuticals; Honoraria (self), Travel / Accommodation / Expenses: Compugen; Honoraria (self), Travel / Accommodation / Expenses: Parker Institute of Cancer Immunology. E.S. Antonarakis: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Janssen; Honoraria (self), Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Sanofi; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Dendreon; Honoraria (self), Advisory / Consultancy: Medivation; Honoraria (self), Advisory / Consultancy: ESSA; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Clovis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Merck; Research grant / Funding (self): Johnson & Johnson; Research grant / Funding (self): Genentech; Research grant / Funding (self): Novartis; Research grant / Funding (self): Bristol-Myers Squibb; Honoraria (institution), Advisory / Consultancy: Eli Lilly; Licensing / Royalties: Qiagen. A.J. Armstrong: Research grant / Funding (institution), Travel / Accommodation / Expenses: Astellas; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Dendreon; Research grant / Funding (institution): Novartis; Advisory / Consultancy: Sanofi Aventis; Research grant / Funding (institution): Genentech/Roche; Research grant / Funding (institution): Constellation; Advisory / Consultancy, Research grant / Funding (institution): Merck; Research grant / Funding (institution): BMS; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Clovis. D.P. Petrylak: Advisory / Consultancy, Research grant / Funding (self): ADA Cap; Advisory / Consultancy: Amgen; Advisory / Consultancy, Research grant / Funding (self): Astellas; Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy, Research grant / Funding (self): Bayer; Shareholder / Stockholder / Stock options: Bellicum; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (self): Bristol Myer Squibb; Advisory / Consultancy, Research grant / Funding (self): Clovis; Advisory / Consultancy, Research grant / Funding (self): Eli Lilly; Research grant / Funding (self): Endocyte; Advisory / Consultancy: Exelixis; Research grant / Funding (self): Genentech; Advisory / Consultancy: Incyte; Research grant / Funding (self): Innocrin; Advisory / Consultancy: Janssen; Research grant / Funding (self): MedImmune; Research grant / Funding (self): Merck; Research grant / Funding (self): Novartis; Advisory / Consultancy, Research grant / Funding (self): Pfizer; Advisory / Consultancy: Pharmacyclics; Research grant / Funding (self): Progenics; Advisory / Consultancy, Research grant / Funding (self): Roche Laboratories; Research grant / Funding (self): Sanofi Aventis; Advisory / Consultancy, Research grant / Funding (self): Seattle Genetics; Shareholder / Stockholder / Stock options: Tyme; Advisory / Consultancy: Urogen. K. Fizazi: Honoraria (self), Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy: AAA; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Clovis; Honoraria (self), Advisory / Consultancy: CureVac; Honoraria (self), Advisory / Consultancy: Incyte; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Orion; Honoraria (self), Advisory / Consultancy: Sanofi. M.E. Salvati: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen; Full / Part-time employment: Kite; Shareholder / Stockholder / Stock options: BMS. H.I. Scher: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Officer / Board of Directors: Asterias Biotherapeutics; Advisory / Consultancy, Travel / Accommodation / Expenses: Ambry Genetics Corporation/Konica Minolta; Non-remunerated activity/ies: Janssen Biotech Inc; Non-remunerated activity/ies: Janssen Research & Development; Travel / Accommodation / Expenses, Non-remunerated activity/ies: ESSA Pharma Inc; Travel / Accommodation / Expenses, Non-remunerated activity/ies: Sanofi Aventis; Advisory / Consultancy, Travel / Accommodation / Expenses: WCG Oncology; Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Menarini Silicon; Advisory / Consultancy, Travel / Accommodation / Expenses: OncLive Insights; Advisory / Consultancy, Travel / Accommodation / Expenses: Physician Education Resource; Research grant / Funding (institution): Illumina; Research grant / Funding (institution): Innocrin Pharma; Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen; Research grant / Funding (institution): Epic Sciences; Research grant / Funding (institution): ThermoFisher; Travel / Accommodation / Expenses: Clovis Oncology; Travel / Accommodation / Expenses: Prostate Cancer Foundation. All other authors have declared no conflicts of interest.
Resources from the same session
4596 - A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis (MBM) (POLARIS)
Presenter: Michael Davies
Session: Poster Display session 3
Resources:
Abstract
1891 - Continuation of annual screening mammograms and breast-cancer mortality in women over 70
Presenter: Xabier Garcia De Albeniz
Session: Poster Display session 3
Resources:
Abstract
5587 - Introducing standardized medical procedure and dynamic decision support program in precision oncology for the community of practice
Presenter: Istvan Petak
Session: Poster Display session 3
Resources:
Abstract
4757 - Effectively using primary care givers in oncology care through capacity building, task sharing and techno-mentoring.
Presenter: Dinesh Pendharkar
Session: Poster Display session 3
Resources:
Abstract
4497 - A single institution review of capecitabine related acute admissions and cost analysis
Presenter: Gemma Dart
Session: Poster Display session 3
Resources:
Abstract
2187 - Health status of middle-aged and older cancer survivors in China: results from the China Health and Retirement Longitudinal Study (CHARLS)
Presenter: Jiarui Li
Session: Poster Display session 3
Resources:
Abstract
5101 - Crossed looks on lung cancer perception and knowledge from general public and physicians in France: results of a two-fold survey
Presenter: Céline Mascaux
Session: Poster Display session 3
Resources:
Abstract
4354 - Knowledge and perception of clinical trials (CTs) and attitude towards participation among Polish oncological patients - A pilot survey
Presenter: Artur Kotowski
Session: Poster Display session 3
Resources:
Abstract
3499 - Achieving best possible cancer treatment outcomes in care pathways through benchmarking; ABC-Benchmarking
Presenter: Anke Wind
Session: Poster Display session 3
Resources:
Abstract
2270 - Impact of 10-day Fulbright Specialist Program (FSP) and Project Pink Blue (PPB) Education Sessions on Medical Oncology knowledge among Doctors that treat cancer in Nigeria
Presenter: Mike Martin
Session: Poster Display session 3
Resources:
Abstract